Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHAT | P28329 | 4/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 13/20 | 0.49 |
| ▸ | CA12 | O43570 | 12/20 | 0.49 |
| ▸ | CA1 | P00915 | 12/20 | 0.49 |
| ▸ | CA2 | P00918 | 12/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | FUT8 | Q9BYC5 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2205546 | 1.00 | CHAT (0.53) | CHATUSP2APEX1CA9CA12 | |
| SCHEMBL2204854 | 1.00 | CHAT (0.53) | CHATUSP2APEX1CA9CA12 | |
| Potassium SCHEMBL2206081 | 0.99 | CHAT (0.52) | CHATUSP2APEX1CA9CA12 | |
| SCHEMBL17565782 | 0.94 | ENPP2 (0.49) | CHATUSP2APEX1CA9CA12 | |
| SCHEMBL16784075 | 0.94 | ENPP2 (0.49) | CHATUSP2APEX1CA9CA12 | |
| SCHEMBL2221609 | 0.92 | CA9 (0.62) | CA9CA12CA1CA2CA14 | |
| SCHEMBL1536256 | 0.92 | CA12 (0.56) | CHATUSP2APEX1CA9CA12 | |
| SCHEMBL18043806 | 0.91 | CA12 (0.47) | CHATUSP2APEX1CA9CA12 | |
| SCHEMBL2205601 | 0.91 | CA12 (0.47) | CHATUSP2APEX1CA9CA12 | |
| SCHEMBL46608 | 0.91 | ENPP2 (0.49) | CHATUSP2APEX1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487503-B2 | Stilbene optical brighteners | 3V SIGMA S.P.A. (IT) | 2016-11-08 | — | — | US | disclosed |
| US-9376405-B2 | Bis-(triazinylamino)-stilbene derivatives | CLARIANT INTERNATIONAL LTD (CH) | 2016-06-28 | — | — | US | disclosed |
| EP-2933253-A1 | STILBENE OPTICAL BRIGHTENERS | 3V SIGMA S.p.A (IT) | 2015-10-21 | — | — | EP | disclosed |
| US-20140339462-A1 | STILBENE OPTICAL BRIGHTENERS | 3V SIGMA S.P.A. (IT) | 2014-11-20 | — | — | US | disclosed |
| EP-2518058-B1 | Novel bis-(triazinylamino)-stilbene derivatives | CLARIANT INT LTD (CH) | 2014-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140339462-A1 | STILBENE OPTICAL BRIGHTENERS | SPIN2B, CYBB, FDFT1 | CHAT 1426/4885USP2 2020/4885APEX1 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.